The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Tetracyclines—An Important Therapeutic Tool for Dermatologists
Published version of a preprint
Abstract
Tetracyclines are a group of antibiotics whose first representative was discovered over 70 years ago. Since then, they have been of great interest in dermatology. In addition to their antibacterial activity, they are able to inhibit metalloproteinases and exhibit anti-inflammatory, anti-apoptotic and antioxidant effects. The side effects have been thoroughly studied over the years, the most characteristic and important ones in daily dermatological practice being: phototoxicity, hyperpigmentation, onycholysis, photoonycholysis, induced lupus erythematosus, and idiopathic intracranial hypertension. In this article, we summarize the use of tetracyclines in infectious diseases and inflammatory dermatoses, and further discuss the instances where the efficacy and safety of tetracyclines have been highlighted over the past few years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Minocycline has been demonstrated to inhibit local inflammatory responses by downregulating the production of inflammatory factors such as TNF‐α. 46”
From Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease (2025) · cites this paper as [46]
In the citing paper
“Previous studies have shown that minocycline can effectively inhibit MMPs, prevent the destruction of periodontal connective tissue, and block alveolar bone resorption. 46”
From Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease (2025) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Comorbidities of hidradenitis suppurativa (acne inversa)
Fimmel, S., & Zouboulis, C. C. (2010) · Dermato-Endocrinology · doi:10.4161/derm.2.1.12490 · Cited by 245
Non-antibiotic properties of tetracyclines and their clinical application in dermatology
Perret, L. J., & Tait, C. P. (2014) · Australasian Journal of Dermatology · doi:10.1111/ajd.12075 · Cited by 68
Research works printed but not linked: 95
- Duggar, 1948, Aureomycin: A product of the continuing search for new antibiotics, Ann. N. Y. Acad. Sci., 51, 177, 10.1111/j.1749-6632.1948.tb27262.x · DOI · Paper page
- Ian, 2001, Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance, Microbiol. Mol. Biol. Rev., 65, 232, 10.1128/MMBR.65.2.232-260.2001 · DOI · Paper page
- Zakeri, 2008, Chemical biology of tetracycline antibiotics, Biochem. Cell Biol., 86, 124, 10.1139/O08-002 · DOI
- Nelson, 1998, Chemical and biological dynamics of tetracyclines, Adv. Dent. Res., 12, 5, 10.1177/08959374980120011901 · DOI
- Griffin, 2011, Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action, Pharmacol. Res., 63, 102, 10.1016/j.phrs.2010.10.004 · DOI · Paper page
- Golub, 1991, Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs, Crit. Rev. Oral Biol. Med., 2, 297, 10.1177/10454411910020030201 · DOI · Paper page
- Stephens, 1954, The structure of aureomycin, J. Am. Chem. Soc., 76, 3568, 10.1021/ja01642a064 · DOI
- Golub, 1992, Host modulation with tetracyclines and their chemically modified analogues, Curr. Opin. Dent., 2, 80
- Livermore, 1990, Antibiotic uptake and transport by bacteria, Scand J. Infect. Dis. Suppl., 74, 15
- White, 1982, Characterization of chlortetracycline (aureomycin) as a calcium ionophore, Biochemistry, 21, 6309, 10.1021/bi00267a041 · DOI
- Nelson, 1993, Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines, J. Med. Chem., 36, 370, 10.1021/jm00055a008 · DOI
- Ryan, 2001, Excessive matrix metalloproteinase activity in diabetes: Inhibition bytetracycline analogues with zinc reactivity, Curr. Med. Chem., 8, 305, 10.2174/0929867013373598 · DOI
- Stezowski, 1975, Chemical structural properties of tetracycline derivatives. 1. Molecular structure a Nd conformation of the free base derivatives, J. Am. Chem. Soc., 98, 6012, 10.1021/ja00435a039 · DOI
- Lambs, 1988, Metal ion-tetracycline interactions in biological fluids. Part 9. Circular dichroism spectra of calcium and magnesiumcomplexes with tetracycline, oxytetracycline, doxycycline and chlortetracycline, and and discussion of their binding modes, Inorg. Chem., 27, 3001, 10.1021/ic00290a022 · DOI
- Stezowski, 1977, Chemical-structural preperties of tetracycline derivatives. 3. The integrity of the conformation of the nonionized free base, J. Am. Chem. Soc., 99, 1117, 10.1021/ja00446a024 · DOI
- Neuvonen, 1976, Interactions with the absorption of tetracyclines, Drugs, 11, 45, 10.2165/00003495-197611010-00004 · DOI · Paper page
- Alexey, 2006, The Tetracycline: Mg2+ Complex: A Molecular Mechanics force, Field. J. Comput. Chem., 27, 1517, 10.1002/jcc.20453 · DOI
- Guerra, 2016, Impact of metal coordination on the antibiotic and non-antibiotic activities of tetracycline-based drugs, Coord. Chem. Rev., 327–328, 188, 10.1016/j.ccr.2016.04.009 · DOI
- Webster, 2016, Status report from the scientific panel on antiobiotic use in dermatology of the American Acne and Rosacea Society:part 1: Antiobiotic prescribing patterns, sources of antibiotic exposure, antibiotic consumption and emergence of antibiotic resistance, impast of alterations in antibiotic prescribing, and clinical sequelae of antibiotic use, J. Clin. Aesthet. Dermatol., 9, 18
- Golub, 1998, Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms, Adv. Dent. Res., 12, 12, 10.1177/08959374980120010501 · DOI · Paper page
- Arvelo, 2006, Metalloproteinases in tumor progression, Review. Invest. Clin., 47, 185
- Roy, 2011, Jack of all trades: Pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS), Pharmacol. Res., 64, 580, 10.1016/j.phrs.2011.06.012 · doi:10.1016/j.phrs.2011.06.012
- Khanapure, 2007, Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers, Curr. Top. Med. Chem., 7, 311, 10.2174/156802607779941314 · DOI · Paper page
- Bahrami, 2012, Tetracyclines: Drugs with huge therapeutic potential, Mini Rev. Med. Chem., 12, 44, 10.2174/138955712798868977 · DOI
- Webster, 2007, Anti-inflammatory activity of tetracyclines, Dermatol. Clin., 25, 133, 10.1016/j.det.2007.01.012 · DOI
- Goodheart, 1979, Further evidence of the role of bivalent cations in leukocyte chemotaxis, J. Reticuloendothel. Soc., 25, 545
- Trachtman, 1996, Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells, Biochem. Biophys. Res. Commun., 229, 243, 10.1006/bbrc.1996.1787 · doi:10.1006/bbrc.1996.1787
- Griffin, 2010, Tetracyclines: A pleitropic family of compounds with promising therapeutic properties. Review of the literature, Am. J. Physiol., 299, C539, 10.1152/ajpcell.00047.2010 · DOI · Paper page
- Kraus, 2005, Antioxidant properties of minocycline: Neuroprotectionin an oxidative stress assay and direct radical-scavenging activity, J. Neurochem., 94, 819, 10.1111/j.1471-4159.2005.03219.x · DOI · Paper page
- Cryns, 1998, Proteases to die for [published correction appears in Genes Dev 1999 Feb 1;13:371], Genes Dev., 12, 1551, 10.1101/gad.12.11.1551 · DOI · Paper page
- Sagar, 2010, Doxycycline in mitochondrial mediated pathway of apoptosis: A systematic review, Anti-Cancer Agents Med. Chem., 10, 556, 10.2174/187152010793498645 · doi:10.2174/187152010793498645
- Vucic, 2012, The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy, Exp. Oncol., 34, 200
- Garrido, 2006, Mechanisms of cytochrome c release from mitochondria, Cell Death Differ., 13, 1423, 10.1038/sj.cdd.4401950 · DOI · Paper page
- Susin, 1999, Molecular characterization of mitochondrial apoptosis-inducing factor, Nature, 397, 441, 10.1038/17135 · DOI · Paper page
- Joza, 2001, Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death, Nature, 410, 549, 10.1038/35069004 · DOI · Paper page
- Chen, 2000, Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease, Nat. Med., 6, 797, 10.1038/77528 · DOI · Paper page
- Riesbeck, 1990, Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrob, Agents Chemother., 34, 167, 10.1128/AAC.34.1.167 · DOI
- Desco, 2021, Minocycline in neurodegenerative and psychiatric diseases: An update, Eur. J. Neurol., 28, 1056, 10.1111/ene.14642 · DOI
- Barza, 1975, Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs, Antimicrob Agents Chemother., 8, 713, 10.1128/AAC.8.6.713 · DOI · Paper page
- Thiboutot, 2009, New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne group, J. Am. Acad. Dermatol., 60, 1, 10.1016/j.jaad.2009.01.019 · DOI · Paper page
- Di Caprio, R., Lembo, S., Di Costanzo, L., Balato, A., and Monfrecola, G. (2015). Anti-inflammatory properties of low and high doxycycline doses: An in vitro study. Mediators Inflamm., 329418. · DOI
- Sorsa, 2006, Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation, Ann. Med., 38, 306, 10.1080/07853890600800103 · DOI · Paper page
- 2017, Third time lucky? Getting a grip on matrix metalloproteinases, J. Biol. Chem., 292, 17975, 10.1074/jbc.H117.806075 · doi:10.1074/jbc.h117.806075
- Hoyt, 2006, Doxycycline modulates nitric oxide production in murine lung epithelial cells, J. Immunol., 176, 567, 10.4049/jimmunol.176.1.567 · DOI
- Cunliffe, 2003, Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle, J. Am. Acad. Dermatol., 49, 218, 10.1067/S0190-9622(03)01153-8 · DOI
- Chen, 2020, Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2, Pharmacol. Res., 159, 105007, 10.1016/j.phrs.2020.105007 · DOI
- Maglie, 2019, Impressive response of erosive pustular dermatosis of the scalp to lymecycline monotherapy, J. Dtsch. Dermatol. Ges., 17, 1177
- Bossuyt, 2003, Lymecycline in the treatment of acne: An efficacious, safe and cost-effective alternative to minocycline, Eur. J. Dermatol., 13, 130
- Grosshans, 1998, A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris, Eur. J. Dermatol., 8, 161
- Berber, 2014, Safety and efficacy comparison of minocycline microgranules vs lymecycline in the treatment of mild to moderate acne: Randomized, evaluator-blinded, parallel, and prospective clinical trial for 8 weeks, J. Drugs Dermatol., 13, 671
- Zhanel, 2004, The glycylcyclines: A comparative review with the tetracyclines, Drugs, 64, 63, 10.2165/00003495-200464010-00005 · DOI · Paper page
- Zhanel, 2018, Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris, Antimicrob. Agents Chemother., 21, e01297-18
- Kaul, 2019, Sarecycline hydrochloride for the treatment of acne vulgaris, Drugs Today, 55, 615, 10.1358/dot.2019.55.10.3045040 · doi:10.1358/dot.2019.55.10.3045040
- Lee, A., and Thomson, J. (2006). Drug-Induced Skin Reactions, Pharmaceutical Press. [2nd ed.].
- Odorici, 2021, Tetracyclines and photosensitive skin reactions: A narrative review, Dermatol. Ther., 34, e14978, 10.1111/dth.14978 · DOI
- Gordon, 1985, Hiperpigmentation of the Skin Associated With Minocycline Therapy, Arch. Dermatol., 121, 618, 10.1001/archderm.1985.01660050070017 · doi:10.1001/archderm.1985.01660050070017
- Abdelghany, 2016, Minocycline-induced hyperpigmentation, Cleve Clin. J. Med., 83, 876, 10.3949/ccjm.83a.16058 · doi:10.3949/ccjm.83a.16058
- Wlodek, 2014, A reminder about photo-onycholysis induced by tetracycline, and the first report of a case induced by lymecycline, Clin. Exp. Dermatol., 39, 746, 10.1111/ced.12350 · DOI
- Czap, 2020, Distal Phototoxic Onycholysis, Dtsch Arztebl Int., 20, 196
- Tan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 25, 1271, 10.1002/art.1780251101 · DOI · Paper page
- Schlienger, 2000, Minocycline-Induced Lupus, Dermatology, 200, 223, 10.1159/000018387 · DOI
- Wall, 2017, Update on Idiopathic Intracranial Hypertension, Neurol. Clin., 35, 45, 10.1016/j.ncl.2016.08.004 · DOI
- Tan, 2020, Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes, Am J Clin Dermatol., 21, 163, 10.1007/s40257-019-00485-z · doi:10.1007/s40257-019-00485-z
- Bababeygy, S.R., Repka, M.X., and Subramanian, P.S. (2009). Minocycline-associated pseudotumor cerebri with severe papilledema. J. Ophthalmol., 203583. · doi:10.1155/2009/203583
- Warner, 2002, Vitamin A in the cerebrospinal fluid of patients with and without idiopathic intracranial hypertension, Ann. Neurol., 52, 647, 10.1002/ana.10377 · doi:10.1002/ana.10377
- Lantos, 2021, Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease, Arthritis Rheumatol., 73, 12, 10.1002/art.41562 · DOI
- Janier, 2021, 2020 European guideline on the management of syphilis, J. Eur. Acad. Dermatol. Venereol., 35, 574, 10.1111/jdv.16946 · DOI · Paper page
- Lanjouw, 2016, European guideline on the management of Chlamydia trachomatis infections, Int. J. STD Aids, 27, 333, 10.1177/0956462415618837 · DOI · Paper page
- 2019, European guideline on the management of lymphogranuloma venereum, J Eur. Acad. Dermatol. Venereol., 33, 1821, 10.1111/jdv.15729 · DOI
- Moi, 2016, European guideline on donovanosis, Int. J. STD Aids, 27, 605, 10.1177/0956462416633626 · doi:10.1177/0956462416633626
- Fralish, 2020, African Tick-Bite Fever, Am. J. Med., 133, 1051, 10.1016/j.amjmed.2020.03.031 · doi:10.1016/j.amjmed.2020.03.031
- Karachitos, 2010, Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells, Biochemistry, 79, 239
- Sapadin, 2006, Tetracyclines: Nonantibiotic properties and their clinical implications, J. Am. Acad. Dermatol., 54, 258, 10.1016/j.jaad.2005.10.004 · DOI · Paper page
- Zaenglein, 2016, Guidelines of care for the management of acne vulgaris, J. Am. Acad. Dermatol., 74, 945, 10.1016/j.jaad.2015.12.037 · DOI · Paper page
- Amin, 1997, Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines, FEBS Lett., 410, 259, 10.1016/S0014-5793(97)00605-4 · DOI
- Monk, 2011, Clinical applications of nonantimicrobial tetracyclines in dermatology, Pharm. Res., 63, 130, 10.1016/j.phrs.2010.10.007 · DOI
- Joshi, 1993, Successful treatment of Sweet’s syndrome with doxycycline, Br. J. Dermatol., 128, 584, 10.1111/j.1365-2133.1993.tb00242.x · DOI
- Tan, 1989, The successful use of minocycline in pyoderma gangrenosum—A report of seven cases and review of the literature, J. Dermatol. Treatment, 1, 23, 10.3109/09546638909086683 · DOI
- Webster, 1994, Inhibition of in vitro granuloma formation by tetracyclines and ciprofloxacin: Involvement of protein kinase C, Arch. Dermatol., 130, 748, 10.1001/archderm.1994.01690060078008 · DOI
- Peterson, 2004, Matrix metalloproteinase inhibitor development and the remodeling of drug discovery, Heart Fail. Rev., 9, 63, 10.1023/B:HREV.0000011395.11179.af · DOI · Paper page
- Kennedy, 2014, Tetracycline: A cure all?, Br. J. Oral Maxillofac. Surg., 52, 382, 10.1016/j.bjoms.2014.01.020 · doi:10.1016/j.bjoms.2014.01.020
- Marsland, 2001, Treatments for chronic palmoplantar pustular psoriasis, Ski. Ther. Lett., 6, 3
- Gulliver, 2016, Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa, Rev. Endocr. Metab. Disord., 17, 343, 10.1007/s11154-016-9328-5 · DOI · Paper page
- Blevins, M. (2021). Atypical Ulcerative Necrobiosis Lipoidica Diabeticorum: A Case Study. Int. J. Low. Extrem. Wounds. · DOI
- Duarte, 2009, Generalized granuloma annulare—Response to doxycycline, J. Eur. Acad. Dermatol. Venereol., 23, 84, 10.1111/j.1468-3083.2008.02707.x · doi:10.1111/j.1468-3083.2008.02707.x
- Burns, 2020, Necrobiosis lipoidica with rapid response to doxycycline, Pediatr. Dermatol., 37, 981, 10.1111/pde.14295 · DOI
- Mumford, 2021, Prurigo pigmentosa: The “keto rash”, Med. J. Aust., 2, 108, 10.5694/mja2.51162 · doi:10.5694/mja2.51162
- Nagashima, 1978, Prurigo pigmentosa-clinical observations of our 14 cases, J. Dermatol., 5, 61, 10.1111/j.1346-8138.1978.tb01049.x · doi:10.1111/j.1346-8138.1978.tb01049.x
- Lu, 2022, Keto Rash: Ketoacidosis-Induced Prurigo Pigmentosa, Mayo Clin. Proc., 97, 20, 10.1016/j.mayocp.2021.11.019 · doi:10.1016/j.mayocp.2021.11.019
- Kurzen, 2008, What causes hidradenitis suppurativa?, Exp. Dermatol., 17, 455, 10.1111/j.1600-0625.2008.00712_1.x · DOI · Paper page
- Yu, 1990, Hidradenitis suppurativa: A disease of follicular epithelium, rather than apocrine glands, Br. J. Dermatol., 122, 763, 10.1111/j.1365-2133.1990.tb06264.x · DOI · Paper page
- Jemec, 1996, Histology of hidradenitis suppurativa, J. Am. Acad. Dermatol., 34, 994, 10.1016/S0190-9622(96)90277-7 · DOI · Paper page
- Kamp, 2011, Hidradenitis suppurativa: A disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa, Br. J. Dermatol., 164, 1017, 10.1111/j.1365-2133.2011.10224.x · DOI
- Albrecht, 2019, Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic, Br. J. Dermatol., 180, 749, 10.1111/bjd.17265 · doi:10.1111/bjd.17265
- Tzellos, 2021, The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study, J. Am. Acad. Dermatol., 85, 369, 10.1016/j.jaad.2020.12.089 · doi:10.1016/j.jaad.2020.12.089
Cited by
Li, H., Wen, X., Gong, X., Wu, Y., Zhao, P., Zhang, Y., Sha, Z., Chang, H., & Chen, X. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10730 · Cited by 17
Metadata
- Authors
- Orylska-Ratynska, M., Placek, W., & Owczarczyk-Saczonek, A.
- Affiliations
- Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury in Olsztyn, Oczapowskiego 2, 10-719 Olsztyn, Poland
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2022-06-13
- Volume
- 19
- Issue
- 12
- Pages
- 7246
- ISSN
- 1660-4601
- PMC
- PMC9224192
- Cited by
- 40
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tetracyclines—An Important Therapeutic Tool for Dermatologists. https://app.cochat.ai/papers/10.3390/ijerph19127246
- The paper
- Orylska-Ratynska, M., Placek, W., & Owczarczyk-Saczonek, A. (2022). Tetracyclines—An Important Therapeutic Tool for Dermatologists. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph19127246
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.